The Rare-Disease Compounder the Market Is Mispricing

A proven biotech platform with a near-blockbuster growth engine, improving cash flows, and rising analyst confidence is trading at a discount to intrinsic value. We believe this setup offers compelling upside over the next 12–18 months.